文献速递心外重症与机械循环支持

心脏移植后原发性移植物功能障碍的区域差异:国际PGD联盟报告

Regional differences in primary graft dysfunction: A report from the international consortium on PGD.
PubMed 文献 · J Heart Lung Transplant · 2025-03-06

该回顾性观察研究纳入2010-2022年14个中心的4101例成人心脏移植受者,比较美国、加拿大和欧洲重度原发性移植物功能障碍(PGD)的发生率、危险因素和结局。结果显示三地区重度PGD发生率相似(8.6%、9.0%、9.6%),危险因素相似,但美国重度PGD后30天和1年死亡率显著低于加拿大和欧洲。

要点

  • 美国、加拿大和欧洲重度PGD发生率相似,但美国重度PGD后死亡率更低。
  • 重度PGD的危险因素包括透析、耐久性LVAD或移植前MCS以及缺血时间。
  • VA-ECMO是三地区管理PGD的首选MCS策略。

核心结论

  • 美国、加拿大和欧洲重度PGD发生率相似,但美国重度PGD后死亡率更低。
  • 分析PGD区域差异有助于制定最佳实践以改善这一灾难性事件的生存。

研究设计与样本

  • 回顾性观察研究,纳入2010-2022年14个中心的4101例连续成人心脏移植受者(美国2077例、加拿大730例、欧洲1294例)。
  • 主要结局为按ISHLT标准定义的重度PGD,采用多变量logistic回归和Cox比例风险模型分析。

主要发现

  • 重度PGD发生率:美国8.6%、加拿大9.0%、欧洲9.6%。
  • 美国和加拿大重度PGD发生率随时间呈上升趋势。
  • 重度PGD后30天死亡率:美国8.9%、加拿大29.8%、欧洲43.9%,美国显著低于加拿大和欧洲。
  • 重度PGD后1年死亡率:美国26.3%、加拿大50.8%、欧洲48.5%,美国显著低于加拿大和欧洲。

临床怎么用

  • VA-ECMO是三地区管理PGD的首选MCS策略。
  • 应关注移植前透析、耐久性LVAD或移植前MCS以及缺血时间等重度PGD危险因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The impact of regional differences on primary graft dysfunction (PGD) after heart transplantation (HT) has not been assessed. This study aims to compare differences in the incidence, risk factors, and outcomes of severe PGD in the US, Canada, and Europe. METHODS: This retrospective, observational study included consecutive adult HT recipients from 14 centers between 2010-2022. The primary outcome was severe PGD as defined by ISHLT criteria. Multivariable logistic regression analyses were conducted. Survival data were analyzed using a proportional hazards Cox model. RESULTS: 4101 HT recipients were included in the analysis (2077 US, 730 Canada, 1294 Europe). Significant differences were observed in recipient cardiovascular risk factors, pre-HT mechanical circulatory support (MCS), ischemic time, and donor age. Severe PGD occurred in 8.6%, 9.0%, and 9.6% of HTs in the US, Canada, and Europe. There was an increasing trend in severe PGD incidence in the US and Canada over time. Risk factors for severe PGD were similar across regions and included pre-HT dialysis, durable LVAD or pre-HT MCS, and ischemic time. VA-ECMO was the preferred MCS strategy for PGD management in all three regions. Thirty-day (8.9%, 29.8%, 43.9%) and 1-year (26.3%, 50.8%, 48.5%) mortality after severe PGD in the US was significantly lower than in Canada and Europe. CONCLUSIONS: The incidence of severe PGD is similar across the US, Canada, and Europe, but with a lower mortality after severe PGD in the US. Analyzing regional differences in PGD can aid in development of best practices for survival after this devastating event.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Guzman-Bofarull J, Ródenas-Alesina E, Moayedi Y, et al. Regional differences in primary graft dysfunction: A report from the international consortium on PGD. J Heart Lung Transplant. 2025. PMID: 40057054. doi:10.1016/j.healun.2025.02.1684

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。